These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 10449286)
21. Comparison of initial combination antiretroviral therapy with a single protease inhibitor, ritonavir and saquinavir, or efavirenz. Lucas GM; Chaisson RE; Moore RD AIDS; 2001 Sep; 15(13):1679-86. PubMed ID: 11546943 [TBL] [Abstract][Full Text] [Related]
22. Residual viraemia in subjects with chronic HIV infection and viral load < 50 copies/ml: the impact of highly active antiretroviral therapy. Palmisano L; Giuliano M; Nicastri E; Pirillo MF; Andreotti M; Galluzzo CM; Bucciardini R; Fragola V; Andreoni M; Vella S AIDS; 2005 Nov; 19(16):1843-7. PubMed ID: 16227792 [TBL] [Abstract][Full Text] [Related]
24. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. Deeks SG; Hecht FM; Swanson M; Elbeik T; Loftus R; Cohen PT; Grant RM AIDS; 1999 Apr; 13(6):F35-43. PubMed ID: 10397555 [TBL] [Abstract][Full Text] [Related]
27. Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study. Wolbers M; Opravil M; von Wyl V; Hirschel B; Furrer H; Cavassini M; Vernazza P; Bernasconi E; Battegay M; Yerly S; Günthard H; Bucher HC; AIDS; 2007 Oct; 21(16):2201-7. PubMed ID: 18090047 [TBL] [Abstract][Full Text] [Related]
28. Suppression of plasma virus load below the detection limit of a human immunodeficiency virus kit is associated with longer virologic response than suppression below the limit of quantitation. Raboud JM; Rae S; Hogg RS; Yip B; Sherlock CH; Harrigan PR; O'Shaughnessy MV; Montaner JS J Infect Dis; 1999 Oct; 180(4):1347-50. PubMed ID: 10479170 [TBL] [Abstract][Full Text] [Related]
29. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy. Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD; Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849 [TBL] [Abstract][Full Text] [Related]
30. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases. Ghani AC; Henley WE; Donnelly CA; Mayer S; Anderson RM AIDS; 2001 Jun; 15(9):1133-42. PubMed ID: 11416715 [TBL] [Abstract][Full Text] [Related]
31. Effect of highly active antiretroviral therapy on cervicovaginal HIV-1 RNA. Cu-Uvin S; Caliendo AM; Reinert S; Chang A; Juliano-Remollino C; Flanigan TP; Mayer KH; Carpenter CC AIDS; 2000 Mar; 14(4):415-21. PubMed ID: 10770544 [TBL] [Abstract][Full Text] [Related]
32. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958 [TBL] [Abstract][Full Text] [Related]
34. Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. Rodes B; García F; Gutierrez C; Martinez-Picado J; Aguilera A; Saumoy M; Vallejo A; Domingo P; Dalmau D; Ribas MA; Blanco JL; Pedreira J; Perez-Elias MJ; Leal M; de Mendoza C; Soriano V; J Med Virol; 2005 Sep; 77(1):23-8. PubMed ID: 16032728 [TBL] [Abstract][Full Text] [Related]
35. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. Hermankova M; Ray SC; Ruff C; Powell-Davis M; Ingersoll R; D'Aquila RT; Quinn TC; Siliciano JD; Siliciano RF; Persaud D JAMA; 2001 Jul; 286(2):196-207. PubMed ID: 11448283 [TBL] [Abstract][Full Text] [Related]
36. Efficacy of nevirapine-based HAART in HIV-1-infected, treatment-naive persons with high and low baseline viral loads. Raffi F; Reliquet V; Podzamczer D; Pollard RB HIV Clin Trials; 2001; 2(4):317-22. PubMed ID: 11590534 [TBL] [Abstract][Full Text] [Related]
37. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. Deeks SG; Wrin T; Liegler T; Hoh R; Hayden M; Barbour JD; Hellmann NS; Petropoulos CJ; McCune JM; Hellerstein MK; Grant RM N Engl J Med; 2001 Feb; 344(7):472-80. PubMed ID: 11172188 [TBL] [Abstract][Full Text] [Related]
38. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort. Paris D; Ledergerber B; Weber R; Jost J; Flepp M; Opravil M; Ruef C; Zimmerli S AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1631-8. PubMed ID: 10606086 [TBL] [Abstract][Full Text] [Related]
39. Virologic outcome and predictors of virologic failure of highly active antiretroviral therapy containing protease inhibitors. Knobel H; Guelar A; Carmona A; Espona M; González A; López-Colomés JL; Saballs P; Gimeno JL; Díez A AIDS Patient Care STDS; 2001 Apr; 15(4):193-9. PubMed ID: 11359661 [TBL] [Abstract][Full Text] [Related]
40. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study. Ledergerber B; Egger M; Erard V; Weber R; Hirschel B; Furrer H; Battegay M; Vernazza P; Bernasconi E; Opravil M; Kaufmann D; Sudre P; Francioli P; Telenti A JAMA; 1999 Dec; 282(23):2220-6. PubMed ID: 10605973 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]